[go: up one dir, main page]

MX2018008658A - Composiciones y metodos para inhibir masp-1 y/o masp-2 y/ o masp-3 para el tratamiento de la hemoglobinuria paroxistica nocturna. - Google Patents

Composiciones y metodos para inhibir masp-1 y/o masp-2 y/ o masp-3 para el tratamiento de la hemoglobinuria paroxistica nocturna.

Info

Publication number
MX2018008658A
MX2018008658A MX2018008658A MX2018008658A MX2018008658A MX 2018008658 A MX2018008658 A MX 2018008658A MX 2018008658 A MX2018008658 A MX 2018008658A MX 2018008658 A MX2018008658 A MX 2018008658A MX 2018008658 A MX2018008658 A MX 2018008658A
Authority
MX
Mexico
Prior art keywords
masp
treatment
paroxysmal nocturnal
nocturnal hemoglobinuria
compositions
Prior art date
Application number
MX2018008658A
Other languages
English (en)
Other versions
MX388278B (es
Inventor
Hans-Wilhelm Schwaeble
Gregory A Demopulos
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corp filed Critical Omeros Corp
Publication of MX2018008658A publication Critical patent/MX2018008658A/es
Publication of MX388278B publication Critical patent/MX388278B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende un anticuerpo monocional inhibidor de MASP-2 que inhibe la activación del complemento dela vía de la lectina y se une específicamente a una porción de la SEQ ID NO: 5, y un anticuerpo monoclonal inhibidor de MASP-3 que se une específicamente al dominio de proteasa de la serina de MASP-3 humano que consiste en los aminoácidos 450 a 711 de la SEQ ID NO: 8 e inhibe la activación del complemento de la vía alternativa, y un vehículo farmacéuticamente aceptable para usarse en el tratamiento de la hemoglobinuria nocturnal paroxismal (PNH).
MX2018008658A 2012-04-06 2013-04-05 Composiciones y metodos para inhibir masp-1 y/o masp-2 y/ o masp-3 para el tratamiento de la hemoglobinuria paroxistica nocturna MX388278B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261621461P 2012-04-06 2012-04-06
PCT/US2013/035488 WO2013180834A2 (en) 2012-04-06 2013-04-05 Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria

Publications (2)

Publication Number Publication Date
MX2018008658A true MX2018008658A (es) 2021-10-19
MX388278B MX388278B (es) 2025-03-18

Family

ID=49325295

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014012045A MX357540B (es) 2012-04-06 2013-04-05 Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de la hemoglobinuria paroxistica nocturna.
MX2018008658A MX388278B (es) 2012-04-06 2013-04-05 Composiciones y metodos para inhibir masp-1 y/o masp-2 y/ o masp-3 para el tratamiento de la hemoglobinuria paroxistica nocturna

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014012045A MX357540B (es) 2012-04-06 2013-04-05 Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de la hemoglobinuria paroxistica nocturna.

Country Status (29)

Country Link
US (3) US20130273053A1 (es)
EP (2) EP3366307B1 (es)
JP (3) JP6366571B2 (es)
KR (2) KR102318623B1 (es)
CN (2) CN104661676A (es)
AU (3) AU2013267909B2 (es)
BR (1) BR112014024793A2 (es)
CA (2) CA2869326C (es)
CL (1) CL2014002694A1 (es)
CY (1) CY1120736T1 (es)
DK (2) DK2833907T3 (es)
ES (2) ES2894944T3 (es)
HR (1) HRP20180671T1 (es)
HU (1) HUE036930T2 (es)
IL (2) IL234991B (es)
IN (1) IN2014KN02324A (es)
LT (1) LT2833907T (es)
MX (2) MX357540B (es)
NO (1) NO2881536T3 (es)
NZ (2) NZ781091A (es)
PL (2) PL2833907T3 (es)
PT (1) PT2833907T (es)
RS (1) RS57266B1 (es)
RU (2) RU2655299C2 (es)
SI (1) SI2833907T1 (es)
SM (1) SMT201800253T1 (es)
TR (1) TR201806939T4 (es)
WO (1) WO2013180834A2 (es)
ZA (1) ZA201408100B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS60541B1 (sr) * 2011-05-04 2020-08-31 Omeros Corp Kompozicije za inhibiciju masp-2 zavisne aktivacije komplementa
JP6445972B2 (ja) * 2012-06-18 2018-12-26 オメロス コーポレーション 様々な疾患および障害の治療のためにｍａｓｐ−１および／またはｍａｓｐ−２および／またはｍａｓｐ−３を阻害する組成物および方法
AU2014229020B2 (en) 2013-03-15 2017-09-28 Omeros Corporation Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
US20140363433A1 (en) 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
JOP20170154B1 (ar) * 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
IL266827B2 (en) 2016-11-28 2025-04-01 Chugai Pharmaceutical Co Ltd Ligand binding molecule with tunable ligand binding activity, its fusion protein with a ligand, pharmaceutical compositions containing them, and method for their production
BR112019008727A2 (pt) * 2016-11-28 2019-07-16 Chugai Seiyaku Kabushiki Kaisha domínio de ligação ao antígeno, e polipeptídeo incluindo seção de transporte
EP3606965A4 (en) * 2017-04-03 2021-01-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MASP-1 ANTIBODY AND METHOD OF USING
TWI818934B (zh) 2017-11-28 2023-10-21 日商中外製藥股份有限公司 可調整配體結合活性的配體結合分子
SG11202004897XA (en) 2017-11-28 2020-06-29 Chugai Pharmaceutical Co Ltd Polypeptide including antigen-binding domain and carrying section
SG11202010925UA (en) 2018-05-29 2020-12-30 Omeros Corp Masp-2 inhibitors and methods of use
US12077577B2 (en) 2018-05-30 2024-09-03 Chugai Seiyaku Kabushiki Kaisha Polypeptide comprising aggrecan binding domain and carrying moiety
KR20220041846A (ko) 2019-07-31 2022-04-01 바이오크리스트파마슈티컬즈,인코포레이티드 경구 보체 인자 d 억제제에 대한 투약 요법
AU2020396565C1 (en) 2019-12-04 2025-05-15 Omeros Corporation MASP-2 inhibitors and methods of use
WO2021113698A1 (en) 2019-12-04 2021-06-10 Omeros Corporation Masp-2 inhibitors and methods of use
KR20220110530A (ko) 2019-12-04 2022-08-08 오메로스 코포레이션 Masp-2 억제자 및 사용 방법
CA3189666A1 (en) 2020-08-18 2022-02-24 William Jason Cummings Monoclonal antibodies, compositions and methods for detecting complement factor d
CN114295594B (zh) * 2021-12-06 2023-09-19 贵州理工学院 一种基于分子信标筛选三螺旋DNA嵌入剂的“turn on”型荧光传感器
GEAP202516705A (en) * 2021-12-10 2025-04-10 Omeros Corp Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof
WO2024251199A1 (zh) * 2023-06-09 2024-12-12 舒泰神（北京）生物制药股份有限公司 特异性结合masp3的抗体以及特异性结合masp3和masp2的多特异性抗体

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
EP0438803B1 (en) 1990-01-26 1997-03-12 Immunomedics, Inc. Vaccines against cancer and infectious diseases
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
AU690528B2 (en) 1992-12-04 1998-04-30 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
EP1238066A2 (en) * 1999-12-02 2002-09-11 Jens Christian Jensenius Masp-3, a complement-fixing enzyme, and uses for it
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
US7043719B2 (en) * 2001-07-23 2006-05-09 Intel Corporation Method and system for automatically prioritizing and analyzing performance data for one or more, system configurations
ES2601143T3 (es) 2002-07-19 2017-02-14 Omeros Corporation Copolímeros tribloque biodegradables, métodos de síntesis de los mismos, e hidrogeles y biomateriales preparados a partir de los mismos
US7666627B2 (en) * 2002-08-08 2010-02-23 Targetex Kft. Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
JP2006518749A (ja) * 2003-02-21 2006-08-17 タノックス インコーポレーテッド 虚血再灌流障害に伴う組織損傷を予防及び治療するための方法
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
WO2005075665A2 (en) * 2004-02-03 2005-08-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with plasma kallikrein (klkb1)
US7803931B2 (en) * 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) * 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
RU2515108C2 (ru) 2005-08-19 2014-05-10 Эббви Инк Иммуноглобулин с двойными вариабельными доменами и его применения
EP1885047B1 (en) * 2006-07-31 2008-12-31 C.R.F. Società Consortile per Azioni Electric generator device actuated by a fluid flow
US8679845B2 (en) 2007-05-31 2014-03-25 University Of Washington B cells modified to reversibly induce accelerated mutagenesis of target genes
CN102164960A (zh) * 2008-09-26 2011-08-24 罗氏格黎卡特股份公司 双特异性抗-egfr/抗-igf-1r抗体
AU2010203712A1 (en) * 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
US20120022543A1 (en) * 2009-03-05 2012-01-26 Smith & Nephew, Inc. System, method, and apparatus for locating a femoral neck guide wire
JP2012533288A (ja) * 2009-07-17 2012-12-27 リグショスピタレト 補体活性化の阻害剤
EA201290286A1 (ru) * 2009-11-05 2013-01-30 Алексион Кембридж Корпорейшн Лечение пароксизмальной ночной гемоглобинурии, гемолитических анемий и патологических состояний с вовлечением внутрисосудистого и внесосудистого гемолиза
US8795973B2 (en) * 2010-11-29 2014-08-05 University of Leceister Methods for identifying inhibitors of mannan-binding lectin associated serine protease (MASP) proteins and uses thereof
EP3287142B1 (en) * 2011-04-08 2021-08-04 University Of Leicester Methods for treating conditions associated with masp-2 dependent complement activation

Also Published As

Publication number Publication date
RU2655299C2 (ru) 2018-05-24
KR20200097808A (ko) 2020-08-19
US20190382505A1 (en) 2019-12-19
KR20150003785A (ko) 2015-01-09
RU2018114903A (ru) 2019-03-04
IL234991B (en) 2020-06-30
AU2013267909B2 (en) 2018-03-01
SMT201800253T1 (it) 2018-07-17
EP2833907B1 (en) 2018-02-28
CN121401408A (zh) 2026-01-27
IL234991A0 (en) 2014-12-31
MX357540B (es) 2018-07-13
JP2021001199A (ja) 2021-01-07
JP2018162307A (ja) 2018-10-18
CL2014002694A1 (es) 2015-08-28
JP2015514117A (ja) 2015-05-18
IL274721B (en) 2022-04-01
DK2833907T3 (en) 2018-05-28
AU2018200721B2 (en) 2020-03-26
PL3366307T3 (pl) 2022-03-07
AU2018200721A1 (en) 2018-02-22
BR112014024793A2 (pt) 2019-08-27
EP2833907A2 (en) 2015-02-11
LT2833907T (lt) 2018-06-11
WO2013180834A3 (en) 2014-04-03
JP6815355B2 (ja) 2021-01-20
CA2869326A1 (en) 2013-12-05
HK1206996A1 (en) 2016-01-22
SI2833907T1 (en) 2018-07-31
EP2833907A4 (en) 2016-03-16
HUE036930T2 (hu) 2018-08-28
EP3366307B1 (en) 2021-07-28
PT2833907T (pt) 2018-05-29
CY1120736T1 (el) 2019-12-11
HRP20180671T1 (hr) 2018-07-13
CA2869326C (en) 2021-09-21
RS57266B1 (sr) 2018-08-31
DK3366307T3 (da) 2021-11-01
AU2013267909A1 (en) 2014-11-27
CA3087933A1 (en) 2013-12-05
AU2020204163A1 (en) 2020-07-09
RU2014144621A (ru) 2016-05-27
US20220242972A1 (en) 2022-08-04
JP6366571B2 (ja) 2018-08-01
PL2833907T3 (pl) 2018-08-31
ES2894944T3 (es) 2022-02-16
MX388278B (es) 2025-03-18
KR102318623B1 (ko) 2021-11-02
EP3366307A1 (en) 2018-08-29
NZ781091A (en) 2022-04-29
ZA201408100B (en) 2022-05-25
IN2014KN02324A (es) 2015-05-01
MX2014012045A (es) 2015-05-15
TR201806939T4 (tr) 2018-06-21
NO2881536T3 (es) 2018-06-30
NZ629675A (en) 2017-02-24
ES2670668T3 (es) 2018-05-31
CN104661676A (zh) 2015-05-27
US20130273053A1 (en) 2013-10-17
RU2018114903A3 (es) 2021-08-12
IL274721A (en) 2020-07-30
NZ727063A (en) 2021-10-29
WO2013180834A2 (en) 2013-12-05
KR102142508B1 (ko) 2020-08-10

Similar Documents

Publication Publication Date Title
MX2018008658A (es) Composiciones y metodos para inhibir masp-1 y/o masp-2 y/ o masp-3 para el tratamiento de la hemoglobinuria paroxistica nocturna.
CL2019002056A1 (es) Composición para el tratamiento de una infección por staphylococcus aureus que contiene solo un anticuerpo o un polipéptido anti leucocidina lukd, lukd aislado o un polipétido del mismo, o una combinación de ambos y portador farmaceuticamente aceptable.(divisional solicitud 201303650)
CL2018000515A1 (es) Virus de la enfermedad de newcastle y usos de los mismos (divisional sol. 2532-2015)
MX2019005402A (es) Terapias de combinacion del inhibidor de arginasa.
EP3725811A3 (en) Compositions for inhibiting masp-2 dependent complement activation
CO2018006299A2 (es) Compuestos novedosos
MX2019009377A (es) Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la espondilitis anquilosante activa.
SV2016005257A (es) Benzimidazol-2-aminas como inhibidores de midh1
PE20141149A1 (es) Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)
NI201500024A (es) Anticuerpos y vacunas para utilizarse en el tratamiento de cánceres por ror1 y para inhibir la metástasis.
ES2667568T3 (es) Anticuerpo anti-B7-H3
ES2617920T3 (es) Métodos para el tratamiento de la coagulación intravascular diseminada mediante la inhibición de la activación del complemento dependiente de MASP-2
MY166776A (en) Humanised anti-ctla4 antibodies
CL2015002485A1 (es) Uso de agonistas de receptor de péptido formilo 2 para tratar enfermedades inflamatorias oculares
BR112015018438A2 (pt) anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento
CO6551683A2 (es) Tratamiento para trastornos gastrointestinales
PE20140173A1 (es) Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MX2018013164A (es) Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa.
MA43650B1 (fr) Formulations/compositions comprenant un inhibiteur de btk
CY1118399T1 (el) Ενωσεις βενζοφουρανιου για την θεραπεια μολυνσεων ιου ηπατιτιδας c
CL2017000845A1 (es) Inhibidores de gingipaina de lisina
EA201690191A1 (ru) Фармацевтическая композиция для замедленного высвобождения ланреотида
MX2011007963A (es) Peptidos neil3 y vacunas que incluyen los mismos.
CL2021001479A1 (es) Péptido; uso de composiciones; composición farmacéutica; uso de un anticuerpo para terapia; uso de un anticuerpo para elisa, inmunohistoquímica y/o formación de imágenes; receptor de linfocito t; y uso de un linfocito t citotóxico activado (divisional de la solicitud n° 201701391)